Patients receive oral MS-275 on days 1, 8, 15, and 22. Courses repeat every 6 weeks in the
absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of MS-275 until the maximum tolerated dose
(MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3
or 2 of 6 patients experience dose-limiting toxicity.

PROJECTED ACCRUAL: Approximately 25-30 patients will be accrued for this study.

Inclusion Criteria

DISEASE CHARACTERISTICS:

- One of the following histologically confirmed diagnoses:

- Acute myeloid leukemia (AML)

- Newly diagnosed de novo AML in patients over 60 years old with the
following poor-risk features:

- Antecedent hematologic disorder

- Complex karyotype or other adverse cytogenetics

- Stem cell immunophenotype

- AML arising from myelodysplastic syndromes (MDS)

- Secondary AML

- Relapsed or refractory AML, including primary induction failure

- MDS

- Poor-risk, defined as the following:

- International Performance Score at least 1.5

- More than 10% marrow blasts

- Cytopenias in at least 2 lineages

- Refractory anemia with excess blasts (RAEB)

- RAEB in transformation

- Chronic myelomonocytic leukemia

- Acute lymphoblastic leukemia (ALL)

- Newly diagnosed de novo ALL in patients over 60 years old with the
following poor-risk features:

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.